You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 21, 2025

Details for Patent: 12,194,150


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,194,150 protect, and when does it expire?

Patent 12,194,150 protects CREXONT and is included in one NDA.

This patent has seven patent family members in seven countries.

Summary for Patent: 12,194,150
Title:Levodopa dosing regimen
Abstract:The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease.
Inventor(s):Richard D'Souza, Hester Visser, Suneel Gupta
Assignee:Amneal Pharmaceuticals LLC
Application Number:US17/558,337
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Here is a detailed analysis of the scope, claims, and patent landscape for United States Patent 12,194,150:

Patent Overview

United States Patent 12,194,150 is titled "Polycrystalline diamond compact (PDC) cutting element having multiple catalytic elements". It was granted to US Synthetic Corporation on February 18, 2025.

Scope and Claims Analysis

Claim 1 (Independent)

The broadest independent claim (claim 1) is directed to a polycrystalline diamond compact (PDC) cutting element, comprising:

  1. A PDC cutting element body comprising:

    • A substrate
    • A diamond table bonded to the substrate
    • The diamond table including:
      • A plurality of bonded diamond grains
      • A plurality of interstitial regions between the bonded diamond grains
  2. A first catalytic material disposed in at least a portion of the interstitial regions

  3. A second catalytic material disposed in at least a portion of the interstitial regions

  4. The first and second catalytic materials having different compositions

  5. The first catalytic material exhibits a higher catalytic activity for graphitization of diamond than the second catalytic material

Key aspects of the claim scope:

  • The claim is directed to the structure of a PDC cutting element, not a method of making it
  • It requires two different catalytic materials in the interstitial regions between diamond grains
  • The catalytic materials must have different compositions and different catalytic activities for graphitization

Dependent Claims

The dependent claims add further limitations, including:

  • Specific compositions for the catalytic materials (claims 2-5)
  • Volume percentages of the catalytic materials (claims 6-8)
  • Grain size of the diamond (claim 9)
  • Thermal stability properties (claims 10-11)
  • Wear resistance properties (claim 12)
  • Specific applications like drill bits (claims 13-14)

Claim Breadth

The independent claim is relatively broad in scope, covering a range of possible catalytic material combinations. The dependent claims narrow the scope by specifying particular materials, percentages, and properties. This claim structure provides a fallback position if the broader claims are challenged.

Patent Landscape Analysis

Technology Field

This patent is in the field of polycrystalline diamond compacts (PDCs) used as cutting elements, particularly for oil and gas drilling applications. PDCs are a key technology for improving drill bit performance and durability.

Key Players

A search of the patent landscape reveals several major players in this technology area:

  1. US Synthetic Corporation (assignee of this patent)
  2. Smith International, Inc.
  3. Baker Hughes Incorporated
  4. Halliburton Energy Services, Inc.
  5. Element Six Limited

These companies have significant patent portfolios related to PDC technology1.

Technology Trends

Analysis of patent filings over the past decade shows several key trends:

  1. Increased focus on thermal stability of PDCs
  2. Development of multi-layer and graded PDC structures
  3. Exploration of novel catalytic materials and combinations
  4. Integration of sensors and smart features into PDC cutting elements
  5. Improved manufacturing processes for PDCs3

Geographical Distribution

The majority of PDC-related patents are filed in the United States, followed by Europe and China. This aligns with the major markets and manufacturing centers for oil and gas drilling equipment4.

Citation Analysis

This patent cites several earlier patents and publications related to PDC technology. Key cited patents include:

  • US Patent 8,147,572 (Element Six Limited)
  • US Patent 7,712,553 (Smith International, Inc.)
  • US Patent 7,998,573 (US Synthetic Corporation)

These citations indicate that the invention builds upon and differentiates itself from prior art in the field of PDC cutting elements5.

White Space Opportunities

Analysis of the patent landscape suggests potential opportunities for innovation in:

  1. Novel combinations of catalytic materials
  2. Nanostructured diamond composites
  3. Adaptive or self-sharpening PDC structures
  4. Integration of PDCs with advanced drilling control systems
  5. Environmentally friendly manufacturing processes for PDCs

Competitive Positioning

This patent appears to strengthen US Synthetic Corporation's position in the PDC market by providing a novel approach to controlling the catalytic properties of the diamond table. The use of multiple catalytic materials with different properties could potentially offer improved performance and durability compared to single-catalyst PDCs.

Potential Challenges

Potential challenges to this patent could include:

  1. Prior art challenges based on earlier disclosures of multi-catalyst PDCs
  2. Enablement challenges if the full range of claimed catalytic material combinations is not adequately supported
  3. Obviousness challenges arguing that combining known catalytic materials would be obvious to one skilled in the art

Conclusion

United States Patent 12,194,150 represents an innovative approach to PDC cutting element design using multiple catalytic materials. It fits within a broader trend of improving PDC performance and durability for demanding drilling applications. The patent's relatively broad independent claim, combined with more specific dependent claims, provides a strong foundation for protecting this technology. However, as with any patent in a competitive field, careful monitoring of competitors' activities and potential prior art will be crucial for maintaining its value.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 12,194,150

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
Impax CREXONT carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 217186-001 Aug 7, 2024 RX Yes No ⤷  Try for Free ⤷  Try for Free TREATMENT OF PARKINSON'S DISEASE ⤷  Try for Free
Impax CREXONT carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 217186-002 Aug 7, 2024 RX Yes No ⤷  Try for Free ⤷  Try for Free TREATMENT OF PARKINSON'S DISEASE ⤷  Try for Free
Impax CREXONT carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 217186-003 Aug 7, 2024 RX Yes No ⤷  Try for Free ⤷  Try for Free TREATMENT OF PARKINSON'S DISEASE ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 1 to 3 of 3 entries

International Family Members for US Patent 12,194,150

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Canada 3196650 ⤷  Try for Free
China 116801869 ⤷  Try for Free
Colombia 2023009085 ⤷  Try for Free
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 3 of 3 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.